TIM-3 genetic variants and risk of Behçet disease in the Iranian population*

Mitra Ataei1, Farinaz Behfarjam1, Zohreh Jadali2

DOI: http://dx.doi.org/10.1590/abd1806-4841.20198022

Abstract: BACKGROUND: Behçet disease is a prototypical systemic autoimmune disease, caused by a complex interplay between environmental and genetic factors. The transmembrane immunoglobulin and mucin domain-3 (TIM-3) is a distinct member of the TIM family that is preferentially expressed on Th1 cells and plays a role in Th1-mediated autoimmune or inflammatory diseases, such as Behçet disease.

OBJECTIVE: The aim of this study was to test the potential association between TIM-3 gene polymorphisms and Behçet disease.

METHODS: Two single-nucleotide polymorphisms of TIM-3 (rs9313439 and rs10515746) were genotyped in 212 patients with Behçet disease and 200 healthy controls. Typing of the polymorphisms was performed using multiplex PCR amplification.

RESULTS: There were no significant differences in allele and genotype frequencies between the Behçet disease patients and controls who were successfully genotyped. Similar results were also found after stratification by gender, age, or clinical features.

STUDY LIMITATIONS: Lack of studies on various racial or ethnic groups and small sample size.

CONCLUSION: This study failed to demonstrate any association between the tested TIM-3 polymorphisms and Behçet disease.

Keywords: Autoimmunity; Behçet syndrome; Polymorphism, single nucleotide

INTRODUCTION

T cells play an important role in the pathogenesis and progression of BD, which is characterized by recurrent oral and genital aphthous ulcers, uveitis, and skin lesions.1 There is also growing evidence of a connection between BD development and genetic variants of immune-related genes.2 Interestingly, some of these variants that may act as predisposing risk factors for BD are T-cell-related molecules (both on the cell surface or internally) and have a close association with T cell activities.3-5

Since BD has been predominantly attributed to be a Th1-driven autoimmune disorder, it seems reasonable to think that variability within Th1 cell-mediated immune response genes may influence disease susceptibility or severity.6 Therefore, some efforts have been made to address this issue and the results have revealed numerous genetic associations between specific single-nucleotide polymorphisms (SNPs) in Th1 related cytokine genes and disease risk.7-9

In recent years, special attention has been given to studies regarding the TIM gene family as a relatively new class of molecules that are involved in the regulation of T cell responses.10 TIM-3, a member of TIM family, is selectively expressed on the surface of differentiated Th1 cells and may play a role in the induction of autoimmune diseases.

The analysis of TIM-3 polymorphisms appears important because the results of different studies indicate an association be-

1 Clinical Genetics Department, National Institute of Genetic Engineering and Biotechnology Tehran, Iran.
2 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Mailing address:
Zohreh Jadali
E-mail: zjadali@yahoo.co.uk

©2019 by Anais Brasileiros de Dermatologia
between the functional variant in TIM-3 and increased risk of auto-
imunity.11,12 To date, no study has been conducted to reveal the
potential relationship between TIM-3 polymorphisms and suscepti-
bility to BD. Thus, the goal of this study was to evaluate the effects
of the two TIM-3 polymorphisms on the risk of BD among an Iran-
ian population.

METHODS

Patients
Venous bloods were drawn from 212 patients with BD (134 men, 78 women) in outpatient clinics at teaching hospitals
affiliated to Tehran University of Medical Sciences.

The revised international criteria for Behçet’s disease
was used for disease diagnosis.13 The mean age of the patients
in this study was 38.38 ± 0.72 years (men: 36.99 ± 0.79 years; wom-
en: 40.76 ± 1.39 years). The mean duration of BD was 14.65 ± 0.59
years (women: 17.06 ± 1.07 years; men: 13.24 ± 0.66 years).
Peripheral blood samples were also taken from 200 healthy
volunteers (143 men, 57 women) referred to the Iranian Blood Trans-
fusion Organization, Tehran, Iran. All controls did not have evi-
dence of BD or other autoimmune diseases and had a mean age of
36.14 ± 0.66 years (men 37.18 ± 0.80 years, women 33.51 ± 0.99 years).

Patients display diverse clinical features encompassing dif-
ferent organ systems to varying degrees. Demographic and clinical
characteristics of patients are found in table 1.

Ethics statement
The proposed experimental protocol was reviewed and ap-
proved by the Research Ethics Board at the Tehran University of
Medical Sciences. Informed consent was obtained from all partici-
pants prior to beginning the research.

SNP selection
The review of the literature proves that genetic variations of
TIM-3 may enhance susceptibility to autoimmune diseases. None-
theless, there is no evidence regarding the association of TIM-3
polymorphisms and BD. Thus, the present study focused on two
SNPs, which were previously investigated in systemic lupus ery-
thematosus and rheumatoid arthritis, two important autoimmune
rheumatic diseases.11,14

DNA extraction
Peripheral blood was collected in EDTA-treated tubes and
DNA was extracted from whole blood using a DNA extraction kit
(MBST - Iran) according to the manufacturer’s instructions.
The quality and quantity of DNA were estimated by aga-
rose gel electrophoresis (1.5% w/v agarose gel in 1 × TBE) stained
with ethidium bromide) and UV spectrophotometry. Genomic DNA
samples were stored at -20 °C until testing.

Primer design
PCR primers pairs were designed by using OLGICO software
(National Biosciences) and purchased from Gene Fanavaran (Te-
hran, Iran). Two reverse primers were designed for each SNP. The
bases at the 3’ end of the reverse primers had variable nucleotide
and the remaining sequence being the same. Details of PCR primers
used in this study are given in table 2. Bold and underlined letters
means different nucleotides between primers.

### Table 1: Clinical and demographic features of the 
BD patients and controls

| Features                  | Patients | Controls |
|---------------------------|----------|----------|
| Number                    | 212      | 200      |
| Age (years)               | 38.38 ± 0.72 | 36.14 ± 0.66 |
| Duration of disease (years) | 14.65 ± 0.59 |        |
| Gender (female/male)      | 78/134   | 57/143   |
| Oral aphthosis            | 209/212  | 98.6%    |
| Genital aphthosis         | 131/212  | 62.8%    |
| Skin lesions              | 127/212  | 59.9%    |
| Ophthalmic manifestations | 147/212  | 69.3%    |
| Joint manifestations      | 110/212  | 51.9%    |
| Neurological involvement  | 25/212   | 11.8%    |
| Vascular involvement      | 20/212   | 9.4%     |
| Other manifestations      | 21/212   | 9.9%     |
| Pathergy phenomenon       | 90/212   | 42.5%    |
| Family history of BD      | 10/212   | 4.7%     |

n/total, n (%), number of individuals/total number of patients or controls
analyzed; BD, Behçet’s disease.

### Table 2: Primer sequences used in studied polymorphisms

| SNPs         | Primer  | Primer sequences               | Product size (bp) |
|--------------|---------|--------------------------------|-------------------|
| rs10515746   | Forward | F:5’AGAGCTGAGGCTACGTGAGT3’      | 437               |
|              | Reverse | R:5’CCCTATCCCTCAATTTACAGACCATA3’|                   |
| rs9313439    | Reverse 1 (T allele) | R:5’CCCTATCCCTCAATTTACAGACCATA3’ | 108               |
|              | Reverse 2 (G allele) | R:5’CCCTATCCCTCAATTTACAGACCATA3’ |               |
|              | Forward | F:5’GCCAGTGCTAGCCCCCTT3’        | 108               |
|              | Reverse 3 (G allele) | R:5’AATACACACAAATCAATGCACTT3’ |               |
|              | Reverse 4(C allele) | R:5’AATACACACAAATCAATGCACTT3’ |               |

SNP, Single Nucleotide Polymorphisms; bp, base pair.
PCR amplification

Genotype determination was carried out by multiplex polymerase chain reaction (multiplex-PCR). Two SNPs spanning the TIM-3 gene were used in our association studies, rs9313439 and rs10515746.

PCR amplification was performed in two separate tubes containing respective reverse primers together with a common forward primer for each allele. The reaction mixture contained 12.5 µL of Taq DNA Pol 2x Master Mix Red (Ampliqon; Denmark), 0.5 µL of each forward and reverse primers (10 pmol/µL), 2 µL of template DNA (1 ng/µL), and 8.5 µL autoclaved distilled water, making the final volume 25 µL. Polymerase chain reaction was performed using on a programmable thermal cycler (Techne Flexigen – Cambridge, United Kingdom).

The amplification conditions were as follows: a pre-denaturation of 94 °C for 5 min, 38 cycles of amplification (95 °C for 1 min, 62 °C for 1 min, and 72 °C for 45 s) and a final extension reaction was performed at 72 °C for 10 min. PCR products were separated on 2% agarose gel by electrophoresis. 10% of samples from the study population were randomly selected for direct sequencing analysis to check the accuracy of genotyping.

Statistical analysis

The chi-squared (\( \chi^2 \)) test was used to compute deviation from the Hardy-Weinberg Equilibrium (HWE) for two SNPs in the cases and controls. Genotypic and allelic frequencies were analyzed in each group using the \( \chi^2 \) and Fisher’s exact tests. T-test analyses were used to evaluate differences in the distribution of demographic variables. Conditional multivariate logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI). Results were considered significant if the p-values were less than 0.05.

Analysis of the data was performed using SPSS v. 11.0 (SPSS, Inc. – Chicago, IL, United States).

RESULTS

In total, 212 BD patients and 200 healthy controls were genotyped for the rs10515746 and rs9313439 SNPs. The allele and genotype frequencies for these SNPs are indicated in table 3.

Statistical analysis revealed that there were no significant differences between the BD patients (n = 212) and controls (n = 200) concerning the frequencies of rs10515746 and rs9313439. This study also did not indicate any associations between the SNPs and clinical presentations related to BD.

Of the 212 patients, 78 (36.8%) were women and 134 (63.2%) were men. The male to female ratio was 1.72 (134:78), and no statistically significant difference was observed in two genetic variants of TIM-3 between male and female patients. Moreover, when the study subjects were grouped according to age, (≤ 30 years and > 30 years), no significant correlation was detected between age groups and genotype frequency for any of the SNPs.

Hardy-Weinberg equilibrium (HWE)

The rs10515746 and rs9313439 SNPs were not in HWE. In the authors’ opinion, departure from HWE was not considered to be due to typing errors, because part of the DNA samples was subjected to direct sequencing and all genotype results were concordant between the two methods (multiplex PCR and direct sequencing). Nonetheless, it is possible that some unidentified factors other than errors in genotyping data may explain deviation from HWE. For instance, the size of the sample or the impact of a complex mix of Iranian populations may have had an influence.

DISCUSSION

The role of dysregulated or abnormal immune responses in BD pathogenesis is well-defined and supports the theory that BD is an autoimmune disorder.13 The initiation and development of BD as an autoimmune disease is the result of a multistep pathogenic process, involving various genetic alterations and environmental factors leading to breakdown of tolerance and induction of an immune response against components of the self.

| Table 3: Frequencies of alleles and genotypes of four TIM-3 SNPs in BD patients and controls |
|---------------------------------------------|
| SNPs       | Alleles/ genotypes | BD n = 212 (%) | Controls n = 200 (%) | \( \chi^2 \) | p    | OR (95% CI) |
|------------|---------------------|----------------|----------------------|----------|------|------------|
| rs10515746 | GG                  | 55 (25.9)      | 46 (23.2)            | 0.408    | 0.96 | 1.03 (0.25-4.21) |
| Alleles    | TG                  | 153 (72.2)     | 148 (74.7)           | 0.121    | 0.53 | 0.87 (0.55-1.36) |
| rs9313439  | TT                  | 4 (1.9)        | 4 (2)                | 0.492    | 0.73 | 0.95 (0.72-1.26) |
| Alleles    | T                   | 162 (38.2)     | 156 (39.4)           | 0.177    | 0.50 | 1.19 (0.72-1.98) |
|            | G                   | 262 (61.8)     | 240 (60.6)           | 0.88     | 0.91 | 0.91 (0.27-3.05) |
|            | CC                  | 35 (16.5)      | 38 (19.1)            | 0.67     | 0.94 | 0.94 (0.71-1.24) |
|            | GC                  | 171 (80.7)     | 156 (78.4)           |          |      |             |
|            | GG                  | 6 (2.8)        | 5 (2.5)              |          |      |             |
|            | C                   | 241 (56.8)     | 232 (58.3)           |          |      |             |
|            | G                   | 183 (43.2)     | 166 (41.7)           |          |      |             |

BD, Behçet disease; OR, odds ratio; 95% CI, 95% confidence interval.
The transmembrane immunoglobulin and mucin domain (TIM) family comprises three genes in humans that encode the proteins TIM-1, TIM-3, and TIM-4. These molecules are expressed on different immune cell types and play important roles in the regulation of immune system. One of these three genes that could encode TIM-3 is specifically expressed by differentiated Th1 cells and acts as a negative regulator of Type 1 immunity. The proposed immunoregulatory role of TIM-3 has been strengthened using some animal models of Th1-mediated autoimmune diseases. For instance, anti-TIM-3 antibody exacerbated Th1-mediated experimental autoimmune encephalomyelitis (EAE) in an established animal model of multiple sclerosis. Similarly, TIM-3 pathway blockade in nonobese diabetic mice led to accelerated diabetes development, which have traditionally been viewed as a Th1-mediated pathology. Moreover, Zhu et al. indicated that administration of galectin-9, which is the best known ligand of TIM-3, causes the selective loss of interferon-gamma-producing cells and suppression of Th1 autoimmunity. Therefore, studying different aspects of this molecule is necessary, allowing a better understanding of the pathological mechanisms of autoimmunity, particularly in Th1-mediated autoimmune disorders, including BD.

Previous studies have reported increased TIM-3 gene expression in peripheral blood mononuclear cells of patients with BD compared with healthy controls. Moreover, a negative correlation between the frequency of TIM-3+ cells and BD activity has been observed in humans. Decreased expression of the TIM-3 ligand (galectin 9) in macrophages from BD-like mice has also been found compared with asymptomatic BD normal mice. Furthermore, injection of galactin 9 in BD-like mice resulted in the amelioration of inflammation, reduction in the severity score, and increased regulatory T cell expression. This evidence encouraged the authors to investigate the possible association of TIM-3 genetic polymorphisms with BD. To the authors’ knowledge, this is the first study relating TIM-3 gene polymorphisms with BD risk.

The results showed no association between TIM-3 SNPs and BD. In addition, there was no association between TIM-3 polymorphisms and BD after stratification by clinical features and gender. The two SNPs selected in the present study have been previously shown to be associated with a variety of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Nevertheless, none of these SNPs showed a significant association with BD. This is in agreement with previous observations that found no association between TIM-3 genetic polymorphisms and autoimmune conditions, including systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid diseases.

Although the present study failed to show any association between the TIM-3 SNPs and BD, there is some evidence that the TIM-3 protein may play a role in the corresponding disease. There are several possible interpretations for these apparently different observations. One possible explanation could be related to the existence of different polymorphism loci in the TIM-3 gene that may influence risk of disease and were not tested in this study. The biological complexity of BD is another option. Because disease development can depend on both genetic and environmental factors, broad heterogeneity of the disease phenotype and predisposing factors may exist across different geographical regions. Therefore, caution must be used in the interpretation of results, and the association of TIM-3 polymorphisms with BD should be investigated using a larger sample size and other racial/ethnic populations.

CONCLUSION

This study failed to find any association between the two polymorphisms of TIM-3 gene (rs9313439 and rs10515746) and susceptibility for BD in Iranian patients. But due to the limited number of studies, its potential implications in disease pathogenesis must not be discarded and further studies are needed to evaluate the exact role of TIM-3 in BD.
TIM-3 genetic variants and risk of Behçet disease in the Iranian population

1. Scherrer MAR, Rocha VB, Garcia LC. Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92:452-64.
2. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun. 2015;64:137-48.
3. Ben Dhifallah I, Chelbi H, Braham A, Hamzaoui K, Houman MH. CTLA-4 +49A/G polymorphism is associated with Behçet’s disease in a Tunisian population. Tissue Antigens. 2009;73:213-7.
4. Chen F, Hou S, Jiang Z, Chen Y, Kijlstra A, Rosenbaum JT, et al. CD40 gene polymorphisms confer risk of Behçet’s disease but not of Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Rheumatology (Oxford). 2012;51:47-51.
5. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behçet’s disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64:4104-13.
6. Li B, Yang P, Zhou H, Zhang Z, Xie C, Lin X, et al. T-bet expression is upregulated in active Behçet’s disease. Br J Ophthalmol. 2003;87:1264-7.
7. Alayli G, Aydin F, Coban AY, Sulü Y, Cantürk F, Bek Y, et al. T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease. Clin Rheumatol. 2007;26:1299-305.
8. Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F. Role of IL-12B promoter polymorphism in Adamantian-betes-Behcet’s disease susceptibility: an involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J Invest Dermatol. 2006;126:1534-40.
9. Sousa I, Shahram F, Francisco D, Davatchi F, Abdollahi BS, Ghaderibarmi F, et al. Brief report: association of CCRI, KLCR4, IL12A-AS1, STAT4, and ERAP1 with Behçet’s disease in Iranians. J Autoimmun. 2010;34:224-8.
10. Freeman GJ, Casasnovas JM, Umetzu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235:172-89.
11. Li WX, Chen GM, Yuan H, Yao YS, Li RJ, Pan HF, et al. Polymorphisms of the TIM-1 and TIM-3 genes are not associated with systemic lupus erythematosus in a Chinese population. Mutagenesis. 2011;26:507-11.
12. Giza M, Kofordi D, Chen L, Bowness P. Is Behçet’s disease a ‘class-1-opathy’? The role of HLA-B*51 in the pathogenesis of Behçet’s disease. Clin Exp Immunol. 2018;191:11-8.
13. Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 2017;410:127-56.
14. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunology. 2016;44:989-1004.
15. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536-41.
16. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093-101.
17. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245-52.
18. Lee JS, Park MJ, Park S, Lee ES. Differential expression of T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) according to activity of Behçet’s disease. J Dermatol Sci. 2012;65:220-2.
19. Shim JA, Park S, Lee ES, Niki T, Hirashima M, Sohn S. Galectin-9 ameliorates herpes simplex virus-induced inflammation through apoptosis. Immunobiology. 2012;217:657-66.
20. Xu J, Yang Y, Liu X, Wang Y. The -1541 C>T and +4259 G>T of TIM-3 polymorphisms are associated with rheumatoid arthritis susceptibility in a Chinese Hui population. Int J Immunogenet. 2011;38:513-8.
21. Mazrouei F, Ganjaliakhi-Hakemi M, Salehi R, Alesahebfosoul F, Etemadifar M, Pouladian M, et al. Association of TIM-1 5383-5397ins/ del and TIM-3 -1541C>T polymorphisms with multiple sclerosis in Isfahan population. Int J Immunogenet. 2016;43:131-4.
22. Brück P, Ramos-Lopez E, Bartsch W, Böhme A, Badenhoop K. TIM-3 polymorphisms in type 1 diabetes families. J Hum Genet. 2008;53:559-64.
23. Inoue N, Watanabe M, Nakaguchi A, Ueda D, Kagawa11, Hidaka Y, et al. Functional polymorphisms affecting Th1 differentiation are associated with the severity of autoimmune thyroid diseases. Endocr J. 2017;64:695-703.

REFERENCES

AUTHORS’ CONTRIBUTIONS

Pedro Secchin Approval of the final version of the manuscript.

Farinaz Behfarjam Approval of the final version of the manuscript.

Zohreh Jaladi Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing and interpreting the data; effective participation in research orientation; intellectual participation in prepaedagogic and/or therapeutic conduct of the cases studied; critical review of the literature; critical review of the manuscript.

How to cite this article: Ataei M, Behfarjam F, Jaladi Z. TIM-3 genetic variants and risk of Behçet disease in the Iranian population. An Bras Dermatol. 2019;94(4):429-33.

An Bras Dermatol. 2019;94(4):429-33,